Parviz_WebPro.png

President & CEO USA

PARVIZ GHARAGOZLOO PhD

Dr. Gharagozloo is the founder of CellOxess LLC and currently serves as its president and Chief Executive Officer. He has over 25 years of experience in Organic and Medicinal Chemistry gained in academia, tech transfer, biotech and pharmaceutical companies in the UK and USA. Prior to CellOxess, he led a group of medicinal chemists at Purdue Pharma in Cranbury, NJ targeting receptors, enzymes and ion-channels for the discovery of novel analgesics. Before joining Purdue in 2000, Dr. Gharagozloo was as the head of medicinal chemistry at Napp pharmaceuticals, a pain specializing company in Cambridge, UK where he led multiple research programs in drug discovery and served on the board of directors. He started his professional research career back in 1990 at the Medical Research Council Technology Center at Mill Hill in London, UK, where he spent 3 years as a postdoc and a further 5 years as a senior scientist and later as the head of medicinal chemistry department. He received his honors BSc degree in Chemistry and PhD in Medicinal chemistry in 1990 at University College London, UK. Dr. Gharagozloo has published extensively in the fields of organic and medicinal chemistry. His work is recognized by a number of international patents and he is the sole inventor of Fertilix.

learn more

 

SWIPE DOWN TO

TRY OUR FERTILITY INDICATOR TOOL

 

MALE OR FEMALE?

LEARN ABOUT WHO'S BEHIND FERTILIX

SWIPE DOWN TO

 

CELLOXESS FOUNDERS HAVE UNMATCHED EXPERTISE IN

PHARMACEUTICAL CHEMISTRY AND REPRODUCTIVE BIOLOGY

COLLECTIVELY AUTHORING OVER 1,000 PEER-REVIEWED PUBLICATIONS &

60 BOOK CHAPTERS IN THE FIELDS OF REDOX BIOLOGY AND FERTILITY

President & CEO

Parviz_WebPro.png

PARVIZ GHARAGOZLOO PhD

Dr. Gharagozloo is the founder of CellOxess LLC and currently serves as its president and Chief Executive Officer. He has over 25 years of experience in Organic and Medicinal Chemistry gained in academia, tech transfer, biotech and pharmaceutical companies in the UK and USA. Prior to CellOxess, he led a group of medicinal chemists at Purdue Pharma in Cranbury, NJ targeting receptors, enzymes and ion-channels for the discovery of novel analgesics. Before joining Purdue in 2000, Dr. Gharagozloo was as the head of medicinal chemistry at Napp pharmaceuticals, a pain specializing company in Cambridge, UK where he led multiple research programs in drug discovery and served on the board of directors. He started his professional research career back in 1990 at the Medical Research Council Technology Center at Mill Hill in London, UK, where he spent 3 years as a postdoc and a further 5 years as a senior scientist and later as the head of medicinal chemistry department. He received his honors BSc degree in Chemistry and PhD in Medicinal chemistry in 1990 at University College London, UK. Dr. Gharagozloo has published extensively in the fields of organic and medicinal chemistry. His work is recognized by a number of international patents and he is the sole inventor of Fertilix.

Chief Scientific Officer

John-Aitken-new_edited.jpg

R. JOHN AITKEN 
PhD,
ScD,
FAHMS,

FRSN,
FRSE,
FAA

DISTINGUISHED EMERITUS LAUREATE PROFESSOR OF BIOLOGICAL SCIENCES, UNIVERSITY OF NEWCASTLE, NEW SOUTH WALES, AUSTRALIA.

CHAIR, HUNTER BRANCH ROYAL SOCIETY OF NSW

Laureate Professor Aitken’s research career began with a PhD in reproductive biology from the University of Cambridge. Following post-doctoral positions at the Institute of Animal Genetics, University of Edinburgh and the University of Bordeaux, he joined the World Health Organization in Geneva, where he managed two WHO task forces within the Human Reproduction Unit. In 1977, he joined the Medical Research Council’s Reproductive Biology Unit, University of Edinburgh, to establish a research group in gamete biology with clinical outreach into male infertility. In 1992, John was awarded an Honorary Professorship within the Faculty of Medicine of Edinburgh University and in 1998 he received a ScD degree from the University of Cambridge in recognition of his research contributions to gamete biology. John has published over 500 research articles, given more than 300 invited lectures and filed 12 patents. He has been elected a Fellow of both the Royal Society of Edinburgh and the Australian Academy of Science, was named as the New South Wales Scientist-of-the-Year in 2012, and 2016 recipient of the prestigious Carl G Hartman award. John Aitken is on the Editorial Boards of 8 journals at the present time. His work has been featured on television [Horizon, Tomorrow’s world, Beyond 2000, Catalyst (2x)], radio (Capital radio, SBS radio, ABC national and local radio as well as the BBC’s Cruicible, Science Now and Medicine Now) and printed media including feature articles in the New Scientist, Nature and the Australian.

Executive Advisory Board

drevet.jpg

JOEL R.
DREVET 
PhD

DEPUTY DIRECTOR GReD LABORATORY (INSERM U1103-CNRS UMR6293, FACULTY OF MEDICINE) PROFESSOR, IMMUNOLOGY & REPRODUCTIVE BIOLOGY.

Professor Drevet's research focuses on the post-testicular stages of sperm maturation during their descent and storage in the epididymis. His main research topic concerns aspects of oxidative stress and its impact on sperm fertilization capacity, sperm nuclear structure integrity and potential transgenerational effects, both in natural reproduction and in assisted reproductive technologies (ART). Cholesterol homeostasis and immune control in the epididymis are other aspects of epididymal physiology on which his team is currently working at both the basic and clinical science levels. Joël Drevet is a member of the European Academy of Andrology (EAA), the European Society of Human Reproduction and Embryo (ESHRE), the North American Society for Studies on Reproduction (SSR) and the French Andrology Society (SALF), a daughter society of the International Society of Andrology (ISA). Joël is managing Editor of the journal BaCA (Basic & Clinical Andrology) the Journal of the French Andrology Society, associate Editor of the journal Asian Journal of Andrology, academic editor of the journal Oxidative Medicine & Cellular Longevity, associate editor of the journal Antioxidants and, academic editor of the journal PLoS ONE. In addition, Joël is currently a member of the review board of Andrology. In recent years, Prof. Drevet has been Associate Editor of Human Reproduction (2011-2016) and a member of the reviewing committee for the journal Biology of Reproduction (2013-2016). The Drevet research team has trained more than 18 doctoral students and published more than 110 articles (factor H:36 and citation index greater than 3900).

SEE THE SCIENCE BEHIND FERTILIX

SWIPE DOWN TO

 

SELECTED SCIENTIFIC PUBLICATIONS

CELLOXESS AUTHORED
CELLOXESS AUTHORED
CELLOXESS AUTHORED
CELLOXESS AUTHORED
CELLOXESS AUTHORED
CELLOXESS AUTHORED
INDEPENDENT
CELLOXESS AUTHORED
CELLOXESS AUTHORED
INDEPENDENT
CELLOXESS AUTHORED
INDEPENDENT
INDEPENDENT
INDEPENDENT
CELLOXESS AUTHORED
INDEPENDENT
CELLOXESS AUTHORED
INDEPENDENT

COMPARE FERTILIX TO OTHER PRODUCTS

SWIPE DOWN TO

 

thank you eshre 2022!

website_couple_pushup_edited.jpg

JOIN THE FERTILIX MOVEMENT

REAL SCIENCE | REAL PRODUCTS | REAL OUTCOMES 

your patients deserve the best